董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bruce T. Bernstein | 男 | Director | 60 | 14.80万美元 | 未持股 | 2024-10-25 |
| Joshua N. Silverman | 男 | Chairman of the Board | 53 | 30.93万美元 | 未持股 | 2024-10-25 |
| Joshua N. Silverman | 男 | Chairman of the Board | 54 | 未披露 | 未持股 | 2024-10-25 |
| Wayne R. Walker | 男 | Director | 64 | 14.80万美元 | 未持股 | 2024-10-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Fady Boctor | 男 | President and Chief Commercial Officer | 47 | 87.51万美元 | 未持股 | 2024-10-25 |
| Mitchell Arnold | 男 | Vice President of Finance and Chief Accounting Officer | 61 | 48.83万美元 | 未持股 | 2024-10-25 |
董事简历
中英对照 | 中文 | 英文- Bruce T. Bernstein
-
Bruce T. Bernstein于2020年加入Petros担任董事。Bernstein先生于2016年至2020年担任Neurotrope的董事会成员，目前担任Synaptogenix, Inc.的董事会成员，Synaptogenix, Inc.是Neurotrope的运营子公司，Neurotrope于2020年12月从Neurotrope分拆出来。Bernstein先生在证券行业拥有30多年的经验，主要担任两个另类金融基金的高级投资组合经理，以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和贷款基金的经理，管理的最高资产为1.4亿美元。此前，他曾担任Omicron Capital，LP的联席总裁，该公司是一家位于纽约的投资公司，他于2001年加入该公司。Omicron Capital专注于对上市小型股公司的直接投资和贷款，管理的最高资产为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于富通投资公司，担任该银行全球证券套利业务部高级副总裁，专门研究股票结构性产品和股票套利，之后担任该银行美国自营投资业务总裁。在加入海富通之前，Bernstein先生是野村证券国际公司股票衍生产品组的主管，专门从事跨境税收套利、国内股票套利和结构性股票互换。Bernstein的职业生涯始于Kidder Peabody，后来升至助理财务主管。Bernstein先生还担任XpresSpa控股公司的董事会成员，该公司是总部设在纽约的世界领先的机场水疗公司。Bernstein先生还是Summit Digital Health的董事会成员，Summit Digital Health是一家总部位于新泽西州的激光血糖监测仪分销商。Bernstein先生拥有纽约城市大学（Baruch）的学士学位。
Bruce T. Bernstein served as a Director for Neurotrope since November 14, 2016 and has been vice chairman of the Board of TAO Synergies since October, 2025. Mr. Bernstein has over thirty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XWELL, Inc., the leading airport spa company in the world, based in New York and Petros Pharmaceuticals, Inc. Mr. Bernstein is also a member of the board of Wrap Technologies Inc., a provider of public safety technology and services, based in Florida. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch). - Bruce T. Bernstein于2020年加入Petros担任董事。Bernstein先生于2016年至2020年担任Neurotrope的董事会成员，目前担任Synaptogenix, Inc.的董事会成员，Synaptogenix, Inc.是Neurotrope的运营子公司，Neurotrope于2020年12月从Neurotrope分拆出来。Bernstein先生在证券行业拥有30多年的经验，主要担任两个另类金融基金的高级投资组合经理，以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和贷款基金的经理，管理的最高资产为1.4亿美元。此前，他曾担任Omicron Capital，LP的联席总裁，该公司是一家位于纽约的投资公司，他于2001年加入该公司。Omicron Capital专注于对上市小型股公司的直接投资和贷款，管理的最高资产为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于富通投资公司，担任该银行全球证券套利业务部高级副总裁，专门研究股票结构性产品和股票套利，之后担任该银行美国自营投资业务总裁。在加入海富通之前，Bernstein先生是野村证券国际公司股票衍生产品组的主管，专门从事跨境税收套利、国内股票套利和结构性股票互换。Bernstein的职业生涯始于Kidder Peabody，后来升至助理财务主管。Bernstein先生还担任XpresSpa控股公司的董事会成员，该公司是总部设在纽约的世界领先的机场水疗公司。Bernstein先生还是Summit Digital Health的董事会成员，Summit Digital Health是一家总部位于新泽西州的激光血糖监测仪分销商。Bernstein先生拥有纽约城市大学（Baruch）的学士学位。
- Bruce T. Bernstein served as a Director for Neurotrope since November 14, 2016 and has been vice chairman of the Board of TAO Synergies since October, 2025. Mr. Bernstein has over thirty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XWELL, Inc., the leading airport spa company in the world, based in New York and Petros Pharmaceuticals, Inc. Mr. Bernstein is also a member of the board of Wrap Technologies Inc., a provider of public safety technology and services, based in Florida. Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).
- Joshua N. Silverman
-
Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
Joshua N. Silverman joined TAO Synergies Inc. (formerly Synaptogenix, Inc.) as a Director and Chairman of the Board in August 2016 and currently serves as Executive Chairman. Mr. Silverman currently serves as the managing member of Parkfield Funding LLC. Mr. Silverman also serves as Interim Chairman, Interim Chief Executive Officer and Interim President of PharmaCyte Biotech, Inc. (Nasdaq: PMCB) since October 2022 and as a director since August 2022. Mr. Silverman was the co founder, and a principal and managing partner of Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm. Since its inception in 2003 until July 2016, Mr. Silverman served as co chief investment officer of Iroquois. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the United States. In addition to TAO Synergies Inc., Mr. Silverman has served as a director and acting Chief Executive Officer of StableX Technologies (Formerly AYRO, Inc.) (Nasdaq: SBLX) since 2020; as Interim Chief Executive Officer, Interim President and Interim Chairman of PharmaCyte Biotech, Inc. (Nasdaq: PMCB); as director of QC Technologies Inc. (Formerly TNF Pharmaceuticals, Inc.) (Nasdaq: QCLS) since September 2018; and as Executive Chairman of Petros Pharmaceutical, Inc. (Nasdaq: PTPI). He previously served as a director of Marker Therapeutics, Inc. from 2016 until 2018 and Protagenic Therapeutics, Inc. from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992. - Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
- Joshua N. Silverman joined TAO Synergies Inc. (formerly Synaptogenix, Inc.) as a Director and Chairman of the Board in August 2016 and currently serves as Executive Chairman. Mr. Silverman currently serves as the managing member of Parkfield Funding LLC. Mr. Silverman also serves as Interim Chairman, Interim Chief Executive Officer and Interim President of PharmaCyte Biotech, Inc. (Nasdaq: PMCB) since October 2022 and as a director since August 2022. Mr. Silverman was the co founder, and a principal and managing partner of Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm. Since its inception in 2003 until July 2016, Mr. Silverman served as co chief investment officer of Iroquois. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the United States. In addition to TAO Synergies Inc., Mr. Silverman has served as a director and acting Chief Executive Officer of StableX Technologies (Formerly AYRO, Inc.) (Nasdaq: SBLX) since 2020; as Interim Chief Executive Officer, Interim President and Interim Chairman of PharmaCyte Biotech, Inc. (Nasdaq: PMCB); as director of QC Technologies Inc. (Formerly TNF Pharmaceuticals, Inc.) (Nasdaq: QCLS) since September 2018; and as Executive Chairman of Petros Pharmaceutical, Inc. (Nasdaq: PTPI). He previously served as a director of Marker Therapeutics, Inc. from 2016 until 2018 and Protagenic Therapeutics, Inc. from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Joshua N. Silverman
-
JoshuaN.Silverman于2016年8月加入Neurotrope，担任董事兼董事会主席，并计划在合并后继续担任Petros的董事兼董事会主席。他目前是Parkfield Funding LLC的联合创始人和管理成员，也是Iroquois Capital Management，LLC“；Iroquois”；的前任负责人和管理合伙人。Silverman先生从2003年到2016年7月担任易洛魁公司联合首席投资官。从2000年到2003年，Silverman先生担任Vertical Ventures，LLC的联席首席投资官，这是一家商业银行。在成立易洛魁之前，Silverman先生是Joele Frank（一家精品咨询公司，专注于并购）的董事。此前，Silverman先生担任美国总统助理新闻秘书。Silverman先生于1992年在利哈伊大学获得文学学士学位。在过去的五年中，Silverman先生担任MGT Capital Investments Inc.，国家控股公司，Alanco Technologies Inc.，ProtagenicTherapeutics，Inc.，TapImmune，Inc.和WPCS International Incorporated的董事会成员。
Joshua N. Silverman has served as a director of the Company since Augt 2022 and as Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since Augt 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previoly, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as a director of AYRO, Inc. (Nasdaq: AYRO), TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), Synaptogenix, Inc. (Nasdaq: SNPX) and Petros Pharmaceutical, Inc. (Nasdaq: PTPI). He previoly served as a director of Marker Therapeutics, Inc. (Nasdaq: MRKR) from 2016 until 2018 and Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992. - JoshuaN.Silverman于2016年8月加入Neurotrope，担任董事兼董事会主席，并计划在合并后继续担任Petros的董事兼董事会主席。他目前是Parkfield Funding LLC的联合创始人和管理成员，也是Iroquois Capital Management，LLC“；Iroquois”；的前任负责人和管理合伙人。Silverman先生从2003年到2016年7月担任易洛魁公司联合首席投资官。从2000年到2003年，Silverman先生担任Vertical Ventures，LLC的联席首席投资官，这是一家商业银行。在成立易洛魁之前，Silverman先生是Joele Frank（一家精品咨询公司，专注于并购）的董事。此前，Silverman先生担任美国总统助理新闻秘书。Silverman先生于1992年在利哈伊大学获得文学学士学位。在过去的五年中，Silverman先生担任MGT Capital Investments Inc.，国家控股公司，Alanco Technologies Inc.，ProtagenicTherapeutics，Inc.，TapImmune，Inc.和WPCS International Incorporated的董事会成员。
- Joshua N. Silverman has served as a director of the Company since Augt 2022 and as Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since Augt 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previoly, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as a director of AYRO, Inc. (Nasdaq: AYRO), TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), Synaptogenix, Inc. (Nasdaq: SNPX) and Petros Pharmaceutical, Inc. (Nasdaq: PTPI). He previoly served as a director of Marker Therapeutics, Inc. (Nasdaq: MRKR) from 2016 until 2018 and Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Wayne R. Walker
-
Wayne R. Walker，自2022年12月起担任本公司董事。沃克先生在公司治理、转型管理、公司重组和破产事务方面拥有超过35年的经验。1998年，沃克创立了国际商业咨询公司Walker Nell Partners，Inc.，并从创立到现在一直担任公司总裁。在创立Walker Nell Partners，Inc.之前，Walker先生在特拉华州威尔明顿的杜邦公司证券与破产小组工作了15年，在公司秘书办公室工作，并担任高级法律顾问。从2022年至今，沃克先生担任AMMO，Inc.（纳斯达克：POWW）的董事，该公司是弹药产品的设计者、生产商和营销商。从2020年12月至今，Walker先生担任AYRO公司（纳斯达克：AYRO）董事，该公司是紧凑型、可持续电动汽车的设计者和制造商。从2018年至今，沃克先生担任Wrap Technologies, Inc.（纳斯达克：WRAP）董事，该公司是现代警务解决方案的创新者，他还担任董事会主席。从2018年至今，Walker先生担任皮特凯恩公司董事和薪酬委员会主席。从2013年到2014年，沃克先生担任BridgeStreet Worldwide，Inc.的董事会主席，该公司是一家提供大型企业住房的全球性公司。从2016年到2018年，沃克担任Last Call Operating Companies的董事会主席，该公司拥有多家全国性餐厅。从2013年到2020年，沃克担任公共慈善机构国家慈善信托的董事会主席。从2018年到2020年，沃克先生担任费城教育委员会副主席。从2020年至今，沃克先生担任Petros Pharmaceuticals, Inc.（纳斯达克：PTPI）的董事，该公司专注于男性健康。沃克先生还担任过许多其他公司和基金会的董事会成员，包括Seaborne Airlines，Inc.，Green Flash Brewery，Inc.，Eagleville Hospital and Foundation。沃克先生拥有天主教大学（华盛顿特区）的法学博士学位和洛约拉大学（新奥尔良）的文学学士学位。他是乔治亚州律师协会颁发的律师执照。他是乔治亚州律师协会、美国律师协会、美国破产协会和周转管理协会的成员。
Wayne R. Walker has over 35 years of experience in corporate governance, turnaround management, corporate restructuring and bankruptcy matters. In 1998, Mr. Walker founded Walker Nell Partners, Inc., an international business consulting firm, and has served as its president from its founding to the present. Before founding Walker Nell Partners, Inc., Mr. Walker worked for 15 years at the DuPont Company in Wilmington, Delaware in the Securities and Bankruptcy group, where he worked in the Corporate Secretary's office and served as Senior Counsel. From 2018 to the present, Mr. Walker has served as a director of Wrap Technologies, Inc. (NASDAQ: WRAP), an innovator of modern policing solutions, where he also serves as Chair of the Nominating and Governance Committee and of the Compensation Committee. From 2018 to the present, Mr. Walker has served as a director of Pitcairn Company and as the Chair of its Compensation Committee. From 2013 to 2014, Mr. Walker served as Chairman of the Board of Directors of BridgeStreet Worldwide, Inc., a global provider of extended corporate housing. From 2016 to 2018, Mr. Walker served as Chairman of the Board of Directors of Last Call Operating Companies, an owner of various national restaurants. From 2013 to 2020, Mr. Walker served as Chairman of the Board of Trustees of National Philanthropic Trust, a public charity. From 2018 to 2020, Mr. Walker served as Vice President of the Board of Education of the City of Philadelphia. From 2020 to the present, Mr. Walker has served as a director of Petros Pharmaceuticals, Inc. (NASDAQ: PTPI), which focuses on men's health, where he also serves as Chair of the Nominating and Governance Committee. Mr. Walker has also served on the board of directors for the following companies and foundations: Seaborne Airlines, Inc., Green Flash Brewery, Inc., and Eagleville Hospital and Foundation. Mr. Walker has a Doctor of Jurisprudence from Catholic University (Washington, DC) and a Bachelor of Arts from Loyola University (New Orleans). He is an attorney licensed by the State Bar of Georgia. He is a member of the State Bar Association of Georgia, American Bar Association, American Bankruptcy Institute and Turnaround Management Association. - Wayne R. Walker，自2022年12月起担任本公司董事。沃克先生在公司治理、转型管理、公司重组和破产事务方面拥有超过35年的经验。1998年，沃克创立了国际商业咨询公司Walker Nell Partners，Inc.，并从创立到现在一直担任公司总裁。在创立Walker Nell Partners，Inc.之前，Walker先生在特拉华州威尔明顿的杜邦公司证券与破产小组工作了15年，在公司秘书办公室工作，并担任高级法律顾问。从2022年至今，沃克先生担任AMMO，Inc.（纳斯达克：POWW）的董事，该公司是弹药产品的设计者、生产商和营销商。从2020年12月至今，Walker先生担任AYRO公司（纳斯达克：AYRO）董事，该公司是紧凑型、可持续电动汽车的设计者和制造商。从2018年至今，沃克先生担任Wrap Technologies, Inc.（纳斯达克：WRAP）董事，该公司是现代警务解决方案的创新者，他还担任董事会主席。从2018年至今，Walker先生担任皮特凯恩公司董事和薪酬委员会主席。从2013年到2014年，沃克先生担任BridgeStreet Worldwide，Inc.的董事会主席，该公司是一家提供大型企业住房的全球性公司。从2016年到2018年，沃克担任Last Call Operating Companies的董事会主席，该公司拥有多家全国性餐厅。从2013年到2020年，沃克担任公共慈善机构国家慈善信托的董事会主席。从2018年到2020年，沃克先生担任费城教育委员会副主席。从2020年至今，沃克先生担任Petros Pharmaceuticals, Inc.（纳斯达克：PTPI）的董事，该公司专注于男性健康。沃克先生还担任过许多其他公司和基金会的董事会成员，包括Seaborne Airlines，Inc.，Green Flash Brewery，Inc.，Eagleville Hospital and Foundation。沃克先生拥有天主教大学（华盛顿特区）的法学博士学位和洛约拉大学（新奥尔良）的文学学士学位。他是乔治亚州律师协会颁发的律师执照。他是乔治亚州律师协会、美国律师协会、美国破产协会和周转管理协会的成员。
- Wayne R. Walker has over 35 years of experience in corporate governance, turnaround management, corporate restructuring and bankruptcy matters. In 1998, Mr. Walker founded Walker Nell Partners, Inc., an international business consulting firm, and has served as its president from its founding to the present. Before founding Walker Nell Partners, Inc., Mr. Walker worked for 15 years at the DuPont Company in Wilmington, Delaware in the Securities and Bankruptcy group, where he worked in the Corporate Secretary's office and served as Senior Counsel. From 2018 to the present, Mr. Walker has served as a director of Wrap Technologies, Inc. (NASDAQ: WRAP), an innovator of modern policing solutions, where he also serves as Chair of the Nominating and Governance Committee and of the Compensation Committee. From 2018 to the present, Mr. Walker has served as a director of Pitcairn Company and as the Chair of its Compensation Committee. From 2013 to 2014, Mr. Walker served as Chairman of the Board of Directors of BridgeStreet Worldwide, Inc., a global provider of extended corporate housing. From 2016 to 2018, Mr. Walker served as Chairman of the Board of Directors of Last Call Operating Companies, an owner of various national restaurants. From 2013 to 2020, Mr. Walker served as Chairman of the Board of Trustees of National Philanthropic Trust, a public charity. From 2018 to 2020, Mr. Walker served as Vice President of the Board of Education of the City of Philadelphia. From 2020 to the present, Mr. Walker has served as a director of Petros Pharmaceuticals, Inc. (NASDAQ: PTPI), which focuses on men's health, where he also serves as Chair of the Nominating and Governance Committee. Mr. Walker has also served on the board of directors for the following companies and foundations: Seaborne Airlines, Inc., Green Flash Brewery, Inc., and Eagleville Hospital and Foundation. Mr. Walker has a Doctor of Jurisprudence from Catholic University (Washington, DC) and a Bachelor of Arts from Loyola University (New Orleans). He is an attorney licensed by the State Bar of Georgia. He is a member of the State Bar Association of Georgia, American Bar Association, American Bankruptcy Institute and Turnaround Management Association.
高管简历
中英对照 | 中文 | 英文- Fady Boctor
Fady Boctor自2020年以来一直担任Petros的总裁兼首席商务官。Boctor先生在制药行业拥有超过20年的经验，涉及广泛的职能，包括品牌和产品组合营销，销售渠道优化，产品组合策略开发和新产品发布。Boctor先生推动了主流男性健康产品线，罕见/孤儿疾病疗法和药物滥用救援模式的收入大幅增长。Boctor先生此前曾担任Metuchen Pharmaceuticals的营销副总裁，自2019年3月起担任该职位。从2017年5月至2019年3月，Boctor先生担任Adapt Pharma，Inc.的营销总监。在加入Adapt Pharma，Inc.之前，Boctor先生于2010年3月至2017年5月在Endo International plc担任过各种职务，最近担任高级品牌/营销经理。Boctor先生拥有哈姆林大学的国际关系学士学位，诺里奇大学的外交硕士学位和曼彻斯特大学商学院的工商管理硕士学位。
Fady Boctor,has served as President and Chief Commercial Officer of Petros since 2020. Mr. Boctor has over 20 years of experience in the pharmaceutical industry, across a wide array of functions including brand and portfolio marketing, sales channel optimization, product portfolio strategy development and new product launches. Mr. Boctor has driven significant revenue growth for mainstream men's health product lines, rare/orphan disease therapeutics, and substance abuse rescue modalities. Mr. Boctor previously served as Vice President of Marketing at Metuchen Pharmaceuticals, a position he held since March 2019. From May 2017 to March 2019, Mr. Boctor served as Director of Marketing for Adapt Pharma, Inc. Prior to joining Adapt Pharma, Inc., Mr. Boctor held various roles at Endo International plc from Mar 2010 to May 2017, most recently holding the position of Senior Brand/Marketing Manager. Mr. Boctor holds a B.A. in International Relations from Hamline University, a Masters in Diplomacy from Norwich University and an M.B.A. from the University of Manchester Business School.- Fady Boctor自2020年以来一直担任Petros的总裁兼首席商务官。Boctor先生在制药行业拥有超过20年的经验，涉及广泛的职能，包括品牌和产品组合营销，销售渠道优化，产品组合策略开发和新产品发布。Boctor先生推动了主流男性健康产品线，罕见/孤儿疾病疗法和药物滥用救援模式的收入大幅增长。Boctor先生此前曾担任Metuchen Pharmaceuticals的营销副总裁，自2019年3月起担任该职位。从2017年5月至2019年3月，Boctor先生担任Adapt Pharma，Inc.的营销总监。在加入Adapt Pharma，Inc.之前，Boctor先生于2010年3月至2017年5月在Endo International plc担任过各种职务，最近担任高级品牌/营销经理。Boctor先生拥有哈姆林大学的国际关系学士学位，诺里奇大学的外交硕士学位和曼彻斯特大学商学院的工商管理硕士学位。
- Fady Boctor,has served as President and Chief Commercial Officer of Petros since 2020. Mr. Boctor has over 20 years of experience in the pharmaceutical industry, across a wide array of functions including brand and portfolio marketing, sales channel optimization, product portfolio strategy development and new product launches. Mr. Boctor has driven significant revenue growth for mainstream men's health product lines, rare/orphan disease therapeutics, and substance abuse rescue modalities. Mr. Boctor previously served as Vice President of Marketing at Metuchen Pharmaceuticals, a position he held since March 2019. From May 2017 to March 2019, Mr. Boctor served as Director of Marketing for Adapt Pharma, Inc. Prior to joining Adapt Pharma, Inc., Mr. Boctor held various roles at Endo International plc from Mar 2010 to May 2017, most recently holding the position of Senior Brand/Marketing Manager. Mr. Boctor holds a B.A. in International Relations from Hamline University, a Masters in Diplomacy from Norwich University and an M.B.A. from the University of Manchester Business School.
- Mitchell Arnold
Mitchell Arnold自2021年以来一直担任Petros的财务副总裁兼首席会计官。自2019年以来，Arnold先生一直担任公司财务副总裁。他为公司带来了超过30年的公共和私人公司财务和会计职位的组织领导经验，在那里他成功地改善了财务绩效、现金流、会计流程、SOX合规和ERP系统。在加入公司之前，Arnold先生于2011年至2018年担任Akrimax Pharmaceuticals，LLC财务会计副总裁，在那里他提供会计和财务，财务管理，风险管理和保险，信息技术和设施管理的战略指导。Arnold先生拥有坦普尔大学的金融工商管理硕士学位和宾夕法尼亚州立大学的会计学士学位。
Mitchell Arnold,has served as the Vice President of Finance and Chief Accounting Officer of Petros since 2021. Mr. Arnold has served as Vice President of Finance of the Company since 2019.Prior to joining the Company, from 2011 to 2018, Mr. Arnold served as Vice President of Financial Accounting at Akrimax Pharmaceuticals, LLC where he provided strategic guidance of accounting and finance, treasury management, risk management and insurance, information technology and facilities management. Mr. Arnold holds a Master of Business Administration degree in Finance from Temple University and a Bachelor of Science degree in Accounting from Pennsylvania State University.- Mitchell Arnold自2021年以来一直担任Petros的财务副总裁兼首席会计官。自2019年以来，Arnold先生一直担任公司财务副总裁。他为公司带来了超过30年的公共和私人公司财务和会计职位的组织领导经验，在那里他成功地改善了财务绩效、现金流、会计流程、SOX合规和ERP系统。在加入公司之前，Arnold先生于2011年至2018年担任Akrimax Pharmaceuticals，LLC财务会计副总裁，在那里他提供会计和财务，财务管理，风险管理和保险，信息技术和设施管理的战略指导。Arnold先生拥有坦普尔大学的金融工商管理硕士学位和宾夕法尼亚州立大学的会计学士学位。
- Mitchell Arnold,has served as the Vice President of Finance and Chief Accounting Officer of Petros since 2021. Mr. Arnold has served as Vice President of Finance of the Company since 2019.Prior to joining the Company, from 2011 to 2018, Mr. Arnold served as Vice President of Financial Accounting at Akrimax Pharmaceuticals, LLC where he provided strategic guidance of accounting and finance, treasury management, risk management and insurance, information technology and facilities management. Mr. Arnold holds a Master of Business Administration degree in Finance from Temple University and a Bachelor of Science degree in Accounting from Pennsylvania State University.